JP2020523004A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020523004A5 JP2020523004A5 JP2019565912A JP2019565912A JP2020523004A5 JP 2020523004 A5 JP2020523004 A5 JP 2020523004A5 JP 2019565912 A JP2019565912 A JP 2019565912A JP 2019565912 A JP2019565912 A JP 2019565912A JP 2020523004 A5 JP2020523004 A5 JP 2020523004A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- amino acid
- acid sequence
- antigen
- binding fragment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 171
- 239000012634 fragment Substances 0.000 claims description 101
- 239000000427 antigen Substances 0.000 claims description 81
- 102000036639 antigens Human genes 0.000 claims description 81
- 108091007433 antigens Proteins 0.000 claims description 81
- 239000008194 pharmaceutical composition Substances 0.000 claims description 41
- 239000013566 allergen Substances 0.000 claims description 33
- 239000000284 extract Substances 0.000 claims description 23
- 235000009131 Betula nigra Nutrition 0.000 claims description 10
- 244000276440 Betula nigra Species 0.000 claims description 10
- 235000009109 Betula pendula Nutrition 0.000 claims description 10
- 241000219430 Betula pendula Species 0.000 claims description 10
- 235000010928 Betula populifolia Nutrition 0.000 claims description 10
- 244000089654 Betula populifolia Species 0.000 claims description 10
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 9
- 235000018185 Betula X alpestris Nutrition 0.000 claims description 8
- 235000018212 Betula X uliginosa Nutrition 0.000 claims description 8
- 238000002198 surface plasmon resonance spectroscopy Methods 0.000 claims description 3
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims 2
- 241001070947 Fagus Species 0.000 description 37
- 235000010099 Fagus sylvatica Nutrition 0.000 description 37
- 125000000539 amino acid group Chemical group 0.000 description 27
- 206010020751 Hypersensitivity Diseases 0.000 description 20
- 208000030961 allergic reaction Diseases 0.000 description 18
- 108010058605 myotrophin Proteins 0.000 description 17
- 102000006392 myotrophin Human genes 0.000 description 17
- 238000000034 method Methods 0.000 description 16
- 102000015764 Eye Proteins Human genes 0.000 description 10
- 108010024515 Eye Proteins Proteins 0.000 description 10
- 208000024891 symptom Diseases 0.000 description 8
- 102000004169 proteins and genes Human genes 0.000 description 7
- 108090000623 proteins and genes Proteins 0.000 description 7
- 241000219427 Fagales Species 0.000 description 6
- 239000003814 drug Substances 0.000 description 5
- 230000001668 ameliorated effect Effects 0.000 description 4
- 229940124597 therapeutic agent Drugs 0.000 description 4
- 230000000172 allergic effect Effects 0.000 description 3
- 208000010668 atopic eczema Diseases 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 2
- 239000000739 antihistaminic agent Substances 0.000 description 2
- 229940124630 bronchodilator Drugs 0.000 description 2
- 239000003246 corticosteroid Substances 0.000 description 2
- 239000000850 decongestant Substances 0.000 description 2
- 239000013604 expression vector Substances 0.000 description 2
- 238000009169 immunotherapy Methods 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 150000007523 nucleic acids Chemical class 0.000 description 2
- 229940023041 peptide vaccine Drugs 0.000 description 2
- UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 description 1
- 229930182837 (R)-adrenaline Natural products 0.000 description 1
- 208000033399 Anaphylactic responses Diseases 0.000 description 1
- 206010010744 Conjunctivitis allergic Diseases 0.000 description 1
- 206010039085 Rhinitis allergic Diseases 0.000 description 1
- 206010070834 Sensitisation Diseases 0.000 description 1
- GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 201000009961 allergic asthma Diseases 0.000 description 1
- 208000002205 allergic conjunctivitis Diseases 0.000 description 1
- 201000010105 allergic rhinitis Diseases 0.000 description 1
- 230000036783 anaphylactic response Effects 0.000 description 1
- 230000001387 anti-histamine Effects 0.000 description 1
- 229940125715 antihistaminic agent Drugs 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 208000024998 atopic conjunctivitis Diseases 0.000 description 1
- 210000003651 basophil Anatomy 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 239000000168 bronchodilator agent Substances 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 229960001334 corticosteroids Drugs 0.000 description 1
- 229940124581 decongestants Drugs 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 229960005139 epinephrine Drugs 0.000 description 1
- -1 epinephrines Substances 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 210000003630 histaminocyte Anatomy 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 230000008313 sensitization Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021074862A JP7162097B2 (ja) | 2017-06-01 | 2021-04-27 | Ｂｅｔ ｖ １に対するヒト抗体およびその使用方法 |
| JP2022146982A JP7458453B2 (ja) | 2017-06-01 | 2022-09-15 | Ｂｅｔ ｖ １に対するヒト抗体およびその使用方法 |
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762513872P | 2017-06-01 | 2017-06-01 | |
| US62/513,872 | 2017-06-01 | ||
| US201762571696P | 2017-10-12 | 2017-10-12 | |
| US62/571,696 | 2017-10-12 | ||
| US201862662165P | 2018-04-24 | 2018-04-24 | |
| US62/662,165 | 2018-04-24 | ||
| PCT/US2018/035366 WO2018222854A1 (en) | 2017-06-01 | 2018-05-31 | Human antibodies to bet v 1 and methods of use thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021074862A Division JP7162097B2 (ja) | 2017-06-01 | 2021-04-27 | Ｂｅｔ ｖ １に対するヒト抗体およびその使用方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020523004A JP2020523004A (ja) | 2020-08-06 |
| JP2020523004A5 true JP2020523004A5 (enExample) | 2021-06-10 |
| JP6963036B2 JP6963036B2 (ja) | 2021-11-05 |
Family
ID=62705709
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019565912A Active JP6963036B2 (ja) | 2017-06-01 | 2018-05-31 | Ｂｅｔ ｖ １に対するヒト抗体およびその使用方法 |
| JP2021074862A Active JP7162097B2 (ja) | 2017-06-01 | 2021-04-27 | Ｂｅｔ ｖ １に対するヒト抗体およびその使用方法 |
| JP2022146982A Active JP7458453B2 (ja) | 2017-06-01 | 2022-09-15 | Ｂｅｔ ｖ １に対するヒト抗体およびその使用方法 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021074862A Active JP7162097B2 (ja) | 2017-06-01 | 2021-04-27 | Ｂｅｔ ｖ １に対するヒト抗体およびその使用方法 |
| JP2022146982A Active JP7458453B2 (ja) | 2017-06-01 | 2022-09-15 | Ｂｅｔ ｖ １に対するヒト抗体およびその使用方法 |
Country Status (17)
| Country | Link |
|---|---|
| US (3) | US10793624B2 (enExample) |
| EP (1) | EP3630814A1 (enExample) |
| JP (3) | JP6963036B2 (enExample) |
| KR (3) | KR102329175B1 (enExample) |
| CN (1) | CN110997713B (enExample) |
| AU (2) | AU2018275657B2 (enExample) |
| BR (1) | BR112019025150B1 (enExample) |
| CA (1) | CA3063588A1 (enExample) |
| CL (3) | CL2019003508A1 (enExample) |
| CO (1) | CO2019013196A2 (enExample) |
| IL (2) | IL298034B2 (enExample) |
| MX (2) | MX2019014430A (enExample) |
| MY (1) | MY198270A (enExample) |
| NZ (2) | NZ782911A (enExample) |
| PH (1) | PH12019550238A1 (enExample) |
| WO (1) | WO2018222854A1 (enExample) |
| ZA (1) | ZA201907513B (enExample) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2919934T3 (es) | 2017-05-05 | 2022-07-29 | Regeneron Pharma | Autoinyector y procedimientos de uso relacionados |
| AU2018275657B2 (en) * | 2017-06-01 | 2022-01-06 | Regeneron Pharmaceuticals, Inc. | Human antibodies to Bet v 1 and methods of use thereof |
| EP4175986A1 (en) * | 2020-07-01 | 2023-05-10 | Regeneron Pharmaceuticals, Inc. | Methods of treating allergy using anti-bet v 1 antibodies |
| CN113041271B (zh) * | 2021-04-14 | 2022-12-27 | 浙江养生堂天然药物研究所有限公司 | 具有预防和抗过敏功效的组合物 |
| EP4444348A4 (en) * | 2021-12-08 | 2025-12-03 | Iggenix Inc | COMBINATIONS FOR ALLERGY THERAPY |
| WO2024200854A1 (en) | 2023-03-31 | 2024-10-03 | Alk-Abelló A/S | Allergen binding antibodies suitable for treating tree pollen allergies |
| WO2024251358A1 (en) | 2023-06-07 | 2024-12-12 | Mabylon Ag | Anti-allergen antibodies and uses thereof |
| WO2024259313A1 (en) | 2023-06-16 | 2024-12-19 | Regeneron Pharamceuticals, Inc. | Medical device packaging and related methods |
| US12319747B2 (en) | 2023-07-03 | 2025-06-03 | Medicovestor, Inc. | Methods of using anti-SP17 immunotherapeutics |
| US20250011403A1 (en) * | 2023-07-03 | 2025-01-09 | Medicovestor, Inc. | Nucleic acids, vectors, and cells that encode anti-sp17 antibodies and other sp17 binding proteins |
| AR134008A1 (es) | 2023-10-02 | 2025-11-26 | Regeneron Pharma | Sistema de seguridad de dispositivo de administración de fármaco |
| US12364777B2 (en) | 2023-10-20 | 2025-07-22 | Medicovestor, Inc. | Homodimeric antibodies for use in treating cancers and methods of use |
| US20250255994A1 (en) * | 2023-11-29 | 2025-08-14 | Medicovestor, Inc. | Dimeric immunoconjugates for use in treating cancers and methods of use |
| US12116410B1 (en) | 2023-12-26 | 2024-10-15 | Medicovestor, Inc. | Methods of manufacturing dimeric antibodies |
| US20250263471A1 (en) | 2024-01-30 | 2025-08-21 | Regeneron Pharmaceuticals, Inc. | Methods of treating allergy using anti-bet v 1 antibodies |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU5411594A (en) | 1992-10-27 | 1994-05-24 | Biomay Produktions- Und Handelsgesellschaft M.B.H. | Molecule fragments (peptides) of the main allergens contained in the pollen of trees of the (fagales) order |
| JPH08501799A (ja) | 1992-12-21 | 1996-02-27 | タノックス バイオシステムズ インコーポレイテッド | アレルゲン特異的ＩｇＡモノクローナル抗体及びアレルギー治療のための関連物質 |
| EP0619323A1 (en) | 1993-04-09 | 1994-10-12 | Schering-Plough | Human monoclonal antibodies and processes and materials for making such antibodies |
| GB0002386D0 (en) | 2000-02-02 | 2000-03-22 | Novartis Nutrition Ag | Therapeutic composition |
| US6849259B2 (en) | 2000-06-16 | 2005-02-01 | Symphogen A/S | Polyclonal antibody composition for treating allergy |
| US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| US20040101920A1 (en) | 2002-11-01 | 2004-05-27 | Czeslaw Radziejewski | Modification assisted profiling (MAP) methodology |
| EP1740946B1 (en) | 2004-04-20 | 2013-11-06 | Genmab A/S | Human monoclonal antibodies against cd20 |
| ITMI20052517A1 (it) * | 2005-12-29 | 2007-06-30 | Lofarma Spa | Varianbtio ipoallergeniche dell'allergene maggiore bet v 1 di polline di betula verrucosa |
| AT503297B1 (de) * | 2006-05-18 | 2007-09-15 | Biomay Ag | Allergen-spezifische antikörper |
| CA2652976C (en) | 2006-06-02 | 2015-08-11 | Regeneron Pharmaceuticals, Inc. | High affinity antibodies to human il-6 receptor |
| GB201002559D0 (en) | 2010-02-15 | 2010-03-31 | Circassia Ltd | Birch peptides for vaccine |
| TWI655207B (zh) * | 2013-07-30 | 2019-04-01 | 再生元醫藥公司 | 抗活化素ａ之抗體及其用途 |
| WO2015027154A2 (en) | 2013-08-23 | 2015-02-26 | Regeneron Pharmaceuticals, Inc. | Diagnostic tests and methods for assessing safety, efficacy or outcome of allergen-specific immunotherapy (sit) |
| AU2018275657B2 (en) * | 2017-06-01 | 2022-01-06 | Regeneron Pharmaceuticals, Inc. | Human antibodies to Bet v 1 and methods of use thereof |
| TWI838389B (zh) | 2018-07-19 | 2024-04-11 | 美商再生元醫藥公司 | 雙特異性抗-BCMAｘ抗-CD3抗體及其用途 |
| EP4175986A1 (en) * | 2020-07-01 | 2023-05-10 | Regeneron Pharmaceuticals, Inc. | Methods of treating allergy using anti-bet v 1 antibodies |
-
2018
- 2018-05-31 AU AU2018275657A patent/AU2018275657B2/en active Active
- 2018-05-31 KR KR1020197036599A patent/KR102329175B1/ko active Active
- 2018-05-31 MX MX2019014430A patent/MX2019014430A/es unknown
- 2018-05-31 CN CN201880049949.7A patent/CN110997713B/zh active Active
- 2018-05-31 US US15/994,294 patent/US10793624B2/en active Active
- 2018-05-31 IL IL298034A patent/IL298034B2/en unknown
- 2018-05-31 CA CA3063588A patent/CA3063588A1/en active Pending
- 2018-05-31 KR KR1020247018848A patent/KR102878718B1/ko active Active
- 2018-05-31 WO PCT/US2018/035366 patent/WO2018222854A1/en not_active Ceased
- 2018-05-31 NZ NZ782911A patent/NZ782911A/en unknown
- 2018-05-31 EP EP18733431.3A patent/EP3630814A1/en active Pending
- 2018-05-31 BR BR112019025150-2A patent/BR112019025150B1/pt active IP Right Grant
- 2018-05-31 MY MYPI2019006625A patent/MY198270A/en unknown
- 2018-05-31 IL IL270894A patent/IL270894B2/en unknown
- 2018-05-31 JP JP2019565912A patent/JP6963036B2/ja active Active
- 2018-05-31 NZ NZ759513A patent/NZ759513A/en unknown
- 2018-05-31 KR KR1020217037411A patent/KR102674000B1/ko active Active
-
2019
- 2019-11-13 ZA ZA2019/07513A patent/ZA201907513B/en unknown
- 2019-11-14 PH PH12019550238A patent/PH12019550238A1/en unknown
- 2019-11-26 CO CONC2019/0013196A patent/CO2019013196A2/es unknown
- 2019-11-29 MX MX2023000390A patent/MX2023000390A/es unknown
- 2019-11-29 CL CL2019003508A patent/CL2019003508A1/es unknown
-
2020
- 2020-08-28 US US17/006,599 patent/US11767358B2/en active Active
-
2021
- 2021-04-27 JP JP2021074862A patent/JP7162097B2/ja active Active
- 2021-10-29 CL CL2021002850A patent/CL2021002850A1/es unknown
- 2021-10-29 CL CL2021002851A patent/CL2021002851A1/es unknown
-
2022
- 2022-01-17 AU AU2022200272A patent/AU2022200272B2/en active Active
- 2022-09-15 JP JP2022146982A patent/JP7458453B2/ja active Active
-
2023
- 2023-08-09 US US18/232,238 patent/US20240083986A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020523004A5 (enExample) | ||
| JP2021112207A5 (enExample) | ||
| JP7458453B2 (ja) | Ｂｅｔ ｖ １に対するヒト抗体およびその使用方法 | |
| RU2014148502A (ru) | Человеческие антитела к fel d1 и способы их применения | |
| JP2015523962A5 (enExample) | ||
| KR102355114B1 (ko) | Il-4r 억제제를 투여함으로써 알레르기 치료 및 알레르겐 특이적 면역요법을 강화시키는 방법 | |
| US20210148929A1 (en) | Diagnostic tests and methods for assessing safety, efficacy or outcome of allergen-specific immunotherapy (sit) | |
| JP2024502471A (ja) | ピーナッツアレルギーを治療するための方法およびｉｌ－４ｒアンタゴニストを投与することによってピーナッツアレルゲン特異的免疫療法を増強する方法 | |
| JP2024544380A (ja) | 抗ＩｇＥ抗体を使用したアレルギー反応の治療 | |
| WO2021255621A1 (en) | Treatment of food allergy using anti-ige antibodies | |
| JP2004533991A5 (enExample) | ||
| AU2021293980B2 (en) | Treatment of food allergy using anti-IgE antibodies | |
| JPWO2022006305A5 (enExample) | ||
| WO2025214333A1 (zh) | 抗tslp抗体治疗与tslp相关的炎症疾病的方法 | |
| HK40016853A (en) | Diagnostic tests and methods for assessing safety, efficacy or outcome of allergen-specific immunotherapy (sit) | |
| HK40016853B (en) | Diagnostic tests and methods for assessing safety, efficacy or outcome of allergen-specific immunotherapy (sit) | |
| EA045437B1 (ru) | Антитела человека к bet v 1 и способы их применения | |
| HK1226483B (en) | Diagnostic tests and methods for assessing safety, efficacy or outcome of allergen-specific immunotherapy (sit) |